Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Glaxo Signs Deal For Epilepsy Drug
September 1, 2008
| A version of this story appeared in
Volume 86, Issue 35
GlaxoSmithKline has formed a collaboration with Valeant Pharmaceuticals to advance retigabine, a neuronal potassium channel opener for the treatment of epilepsy. Valeant will grant GSK worldwide development and commercialization rights to the compound and other backup compounds in exchange for a $125 million payment. GSK will also pay Valeant up to $545 million upon reaching certain milestones. Valeant has completed two Phase III clinical trials on the drug and expects to file a New Drug Application with FDA early next year.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter